logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ESMO 2018 – Combination immunotherapy with added danvatirsen in recurrent metastatic head and neck cancer doubles response rate over durvalumab monotherapy

An update to the SCORES phase 1b/2 study in PD-L1-naïve recurrent metastatic head and neck cancer (rmHNC) patients reports an overall response rate of 23%.